ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42223137

Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.

Bekaii-Saab TS and 26 others. J Clin Oncol, 2026. Cited by 3 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial. Papers, record 42223137. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42223137

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase III FIGHT-302 Trial.
PubMed
Journal
J Clin Oncol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-10-08
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bekaii-Saab TSTanios Shttps://orcid.org/0000-0001-7721-1699
2Melisi DDavidehttps://orcid.org/0000-0002-4031-7585
3Wilmink HHanneke
4Garufi CCarlo
5Tran NNguyenhttps://orcid.org/0000-0002-6104-6489
6Tortora GGiampaolohttps://orcid.org/0000-0002-1378-4962
7De Braud FFilippohttps://orcid.org/0000-0003-0103-730X
8Frodin JEJan-Erik
9Lonardi SSarahttps://orcid.org/0000-0002-7593-8138
10Lin EEmily

1 to 10 of 27Source PubMed

See all 27 authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholangiocarcinomaMajor topic
Receptor, Fibroblast Growth Factor, Type 2Major topic
Bile Duct NeoplasmsMajor topic
PyrimidinesMajor topic
MorpholinesMajor topic
PyrrolesMajor topic
Humans
Middle Aged
Female
Aged
Male
Adult
Gene Rearrangement
Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
Progression-Free Survival
Gemcitabine
Cisplatin

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03656536A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic CholangiocarcinomaDerived from the trialYes

Source ClinicalTrials.gov

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137,561,981The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.JCO Precis Oncol2023https://conductscience.org/library/papers/37561981PubMed
229,740,198Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.Sci Rep2018https://conductscience.org/library/papers/29740198PubMed
341,372,578Cholangiocarcinoma 2026: status quo, unmet needs and priorities.Nat Rev Gastroenterol Hepatol2026https://conductscience.org/library/papers/41372578PubMed
435,176,488Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.J Mol Diagn2022https://conductscience.org/library/papers/35176488PubMed
524,560,108Intrahepatic cholangiocarcinoma.Surg Oncol Clin N Am2014https://conductscience.org/library/papers/24560108PubMed
636,206,041FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.Clin Cancer Res2023https://conductscience.org/library/papers/36206041PubMed
731,371,345Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.Cold Spring Harb Mol Case Stud2019https://conductscience.org/library/papers/31371345PubMed
840,381,735Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.J Hepatol2025https://conductscience.org/library/papers/40381735PubMed
933,218,975Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.Cancer Discov2021https://conductscience.org/library/papers/33218975PubMed
1028,034,880Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.Cancer Discov2017https://conductscience.org/library/papers/28034880PubMed

1 to 10 of 22

See all 22 references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42,910,203Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant Oncology.Liver Cancer2026https://conductscience.org/library/papers/42910203PubMed
42,882,770Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study.Cancers (Basel)2026https://conductscience.org/library/papers/42882770PubMed
42,881,857
Molecularly Guided Therapy and the Tumor Microenvironment in Advanced Cholangiocarcinoma: Current Evidence and Emerging Strategies Targeting FGFR2, HER2, and IDH1 with Pemigatinib, Zanidatamab, and Ivosidenib.
J Clin Med2026https://conductscience.org/library/papers/42881857PubMed
42,863,180"Our patients deserve better"-roadblocks to optimal care in biliary malignancies.ESMO Open2026https://conductscience.org/library/papers/42863180PubMed
42,742,882Integrating locoregional therapy with systemic and emerging cellular therapies in advanced intrahepatic cholangiocarcinoma.Discov Oncol2026https://conductscience.org/library/papers/42742882PubMed
42,691,210Highlights of ASCO 2026.Oncologist2026https://conductscience.org/library/papers/42691210PubMed
42,587,090Precision oncology needs precision trial design: lessons from FGFR2-rearranged cholangiocarcinoma.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42587090PubMed
42,488,106Salvage resection for FGFR2 fusion-positive intrahepatic cholangiocarcinoma after pemigatinib therapy: a case report and literature review.Front Oncol2026https://conductscience.org/library/papers/42488106PubMed

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263

Source NCBI Gene

Drugs3

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CISPLATINCHEMBL11359Derived from the trial1https://conductscience.org/library/drugs/CHEMBL11359ChEMBL
PEMIGATINIBCHEMBL4297522Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4297522ChEMBL
GEMCITABINECHEMBL888Derived from the trial1https://conductscience.org/library/drugs/CHEMBL888ChEMBL

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42223137

GET https://conductscience.org/api/papers/v1/42223137/authors?page=2

API referenceFor AI assistants